In the present study, we constructed a CD8+ T cell-associated prognostic signature to evaluate the clinical outcomes and anti-cancer immunotherapeutic sensitivity of GC and validated the translatability to the clinical setting via retrospective analysis of specimens from multiple distinct populations. Here, CD8A is linked to gastric cancer.